Physician profile
Mohammad I Dotani
NPI 1508854175
$4,250.40
in general payments reported to CMS, 2019-2025
14 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $157 · 2021: $110 · 2022: $2,858 · 2023: $114 · 2024: $198 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,534.11 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $606.39 | 2019-2025 | Lifevest |
| Ancora Heart, INC. | $250.17 | 2022 | |
| Pfizer INC. | $193.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $172.41 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $152.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.96 | 2019-2020 | |
| Amgen INC. | $61.92 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $44.69 | 2023-2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $26.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.52 | 2019 | |
| Zoll Circulation INC | $14.43 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.89 | 2024 | Eliquis |
| Edwards Lifesciences Corporation | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Dotani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.